The Battle for Genetic Signatures

Good morning, Armchair Army,

Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.

We are in the second act of our boardroom battle between BCAL and Genetic Signatures.

Yesterday, BCAL moved up to own 18.50% of the company.

… and discussions of a merger between Microba and Genetic Signatures emerged.

It feels like one big WWE headline match.

“The battle for the cash box of Genetic Signatures.”

In the blue corner…

BCAL Diagnostics.

Weighing in with an 18.5% stake and no invitation from the board.

In the red corner…

Microba Life Sciences.

No stake. No offer… yet.

But rumblings of a “merger”.

The prize? 

A diagnostics company with $22 million in cash and an ~$18 million market cap.

Let’s get ready to rumble!

But first…

Control Bionics (ASX: CBL) secures a US Medicare billing code for UnoTouch Omni devices reimbursed at US$9,600. (CBL, held, Armchair Pick 🪑)

🪑 Earlier, CBL signed an exclusive distribution agreement with US-based NextLevel Assistive Technology on a “new range of iOS-based speech devices”.

Up to 1,000 devices in the first 12 months.

(Quick maths on that is US$9.6 million in net revenue)

Now I don’t expect CBL to access all of that revenue; this is a distribution agreement, after all.

But it means that CBL bears none of the cost of distribution or sales, but will get a portion of that top-line sales figure.

The reimbursement effectively “unlocks” NextLevel’s ability to sell the product, a product that the CEO & Founder started to promote one month ago:

This continues CBL’s move from a “direct sales model” to a “distribution model” for its go-to-market strategy in the US for its assistive technology products.

A low-cost way to leverage other people’s sales force and clip the ticket on the way through.

Nice job.

Biome Australia (ASX: BIO) secures an exclusive agreement with H&S Global to launch its Activated Probiotics range in China. (BIO)

🪑 There have been some great Australian companies that have sold products that have taken off in China.

A2 Milk and Capilano Honey come to mind.

Will Biome’s probiotic range be next?

Enlitic Inc. (ASX: ENL) deploys its AI-based Ensight platform with Radiology Consultants of Iowa - US$143K total contract value and US$40K in ARR. (ENL)

🪑 Not a huge deal in number terms, but it shows ENL's growing customer base.

These smaller deals add up, particularly when pursuing a “land and expand” model.

ENL SPP closes Friday.

The FDA has approved the RAS inhibitor Daraxonrasib from Revolution Medicines for Metastatic Pancreatic Cancer. (Oncology News)

🪑 This was the drug that got a standing ovation at ASCO earlier this year.

Strong validation for the RAS inhibitor technology, and it puts pancreatic cancer in the spotlight.

ASX-listed Amplia (ASX: ATX, held) is also developing a pancreatic cancer treatment and recently announced a deal with Eli Lilly to evaluate its product in combination with their RAS inhibitor.

… it's the direction the industry is heading, and ATX is positioning itself in the middle of it with its combination therapy that makes other drugs work better.

Trajan (ASX: TRJ) reports FY26 revenue of $161 million, down 3.1%, with group nEBITDA down 14.7% to $13.2 million. (TRJ)

🪑 That’s a decent revenue miss. Guidance set at $170 million.

… but at a sub-$30 million market cap, will the market actually care?

Mayne Pharma (ASX: MYX) reports $383.7M in revenue (down 6%) and $31.2M net profit after tax for FY26. (MYX)

🪑 As the CEO Aaron Gray said in his comments, FY26 was full of disruptions, but the company did manage to reset the foundations with the launch of the DistributeRx platform.

It will be interesting to see how the company grows from here.

Oneview Healthcare (ASX: ONE) reports a 14% drop in total revenue to €5.48M for H1 2026, with a 30% reduction in net loss to €5.49M. (ONE)

🪑 Detailed write-up from Next Investors this morning: Epic pipeline grows to 16 deals representing 19,860 hospital beds - in just 98 days...

Before we dive into the boardroom battle, let’s roll the “highlights package”.

Genetic Signatures (ASX: GSS) is an ASX-listed company that has developed (and is commercialising) a PRC diagnostics kit for Gastrointestinal Parasite Detection.

In 2024, the company raised $30 million following FDA clearance of its EasyScreen PCR test.

A fancy new CEO was hired.

But it took the company eight months after FDA clearance to secure the first sales.

Commercialisation was slow.

The company began pruning its innovation pipeline.

That fancy CEO?

She got a 50% pay cut and resigned.

(Interestingly, she’s now on the board of Clarity Pharmaceuticals)

Heavy selling over the next 6 months from major shareholder Asia Union Investments.

Which sold its final stake in Genetic Signatures to BCAL Diagnostics back in July for ~$1.4M in exchange for a ~10% stake in the company.

Genetic Signatures hit back immediately with an announcement saying that it was not notified of BCAL’s intention to acquire the shares:

Reading between the lines… this investment from BCAL was hostile.

This was effectively confirmed in an investor call yesterday, where the new CEO of Genetic Signatures said that “there have been no discussions between BCAL and Genetic Signatures”.

… if things were friendly, you would have expected Genetic Signatures to pick up the phone and call their new top shareholder sometime in the last two months.

Yesterday, things got more interesting.

BCAL buys another ~8% of Genetic Signatures' shares from one of the funds (Perennial) at a premium (8 cents).

This puts BCAL at an 18.5% stake.

Again, Genetic Signatures hits back…

An announcement that there are “Merger discussions with Microba”.

No deal. No letter of intent.

… just discussion.

But each company has hired advisors for a transaction.

All of this landed yesterday.

The exact morning that the Managing Director had a scheduled public investor call to discuss the FY26 results.

I dialled in.

(and got my popcorn out)

The first 20 minutes covered Genetic Signatures' end-of-financial-year results.

Boring! 

Get to the good stuff…

Finally, at question time, we got a peek behind the curtain from the boardroom battle.

FIRST, it was confirmed that Genetic Signatures and BCAL have had no communication.

SECOND, when asked, “Why merge with Microba?” Maria suggested corporate overhead savings, complementary business in the “gut health” space, and the potential for a shared distribution network were the key reasons.

FINALLY, when asked, “Who was the right partner, BCAL or Microba?”, Maria gave a diplomatic answer. “We will look at every opportunity, and make a recommendation to shareholders when each proposal comes to the board”.

… alright, those are the facts.

Now for some opinion.

First, to understand what is going on here, we need to understand why both Microba and BCAL would be interested in Genetic Signatures.

FIRST, Genetic Signatures is a cash box.

The company has $22 million in the bank and an $18 million market cap.

Taking over the company (or merging it into an existing business) gets your foot on a large amount of cash.

Think of it like a “Capital Raise” but with a business attached.

Get the cash + the business.

Keep the good bits, jettison the rest.

SECOND, the strategic reason.

For Microba…

Genetic Signatures sells diagnostic test kits to pathology labs. Microba’s number one shareholder is Sonic Healthcare (largest network of pathology labs in Australia).

Real synergies exist if Microba can negotiate distribution deals between Sonic Healthcare and Genetic Signatures to better commercialise its diagnostics products.

For BCAL…

Right now BCAL is focused on commercialising its diagnostic test for breast cancer in Australia (along with two other in-licensed tests).

To take Breast Test international, BCAL could leverage Genetic Signatures' established commercial operations in the US and the UK.

This includes people, labs, team and know-how.

BCAL was very strategic in staying under the 19.99% threshold; going over that level would trigger the takeover provisions.

But 18.5% is a strong blocking stake for any potential merger or transaction that doesn’t involve them.

This gives BCAL “optionality”.

In order for BCAL to make a takeover play for Genetic Signatures:

Ultimately, its shareholders who get to vote.

What about Microba?

For Microba, the path to merging (and getting its foot on the cash box) is a bit longer…

Even if Microba makes a bid for Genetic Signatures, BCAL would have a “blocking stake” to prevent any merger or transaction.

This is in addition to convincing the other shareholders that a merger with Microba is the right move.

This means Microba doesn’t just have to negotiate with the existing major shareholders, but also with BCAL. 

The exact company it is going head-to-head with.

Microba could buy up its own stake in Genetic Signatures to force BCAL to negotiate with them (and create a bit of a stalemate).

Then it becomes a game of chicken. Which is good for no one.

There is a concept in negotiations (one of my all-time favourites); it's called a BATNA.

Best alternative to the negotiated agreement.

It doesn’t necessarily give you more leverage, but it does help you to walk away from a bad deal.

Normally, you negotiate a BATNA in the shadows.

It empowers you, but doesn’t affect your live deal.

The potential merger between Microba and Genetic Signatures is not a BATNA.

It is (in my opinion) a deliberate play to ensure that BCAL doesn’t lowball an offer.

Going public with the negotiations is the tell.

You don’t show your cards unless you want the other side to see.

Which tells me in this situation, Microba is probably the stalking horse to get the best deal possible for Genetic Signatures.

Microba could still make a play, but it will have to make a juicy offer to BCAL to prevent them from blocking any merger.

Ultimately, shareholders decide the fate of the company.

Not the board, not management, not any of the parties involved.

The shareholders.

But because BCAL has 18.50% of the company, it is in pole position right now.

Quick disclosure: I owned Genetic Signatures for a little while as one of my “tax loss trades”, but I sold my stock earlier this week at breakeven.

(I left a bit of money on the table as the stock went up the day after… but that’s okay)

As a small shareholder, I’m not looking to “bet” on the share price moving on the boardroom battle; I’d rather allocate my capital to other higher-conviction picks.

See you tomorrow, and hopefully some of you today, at the Armchair After Market event.

The Armchair Analyst.